Last reviewed · How we verify
NCT02949427
The Oronasal Microbiota in Pediatric Oncology Patients
trial in Acute Myeloid Leukemia in 62 participants. Completed in 29 March 2023.
25 July 2022
Quick facts
| Lead sponsor | St. Jude Children's Research Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 62 |
| Start date | 6 March 2017 |
| Primary completion | 25 July 2022 |
| Estimated completion | 29 March 2023 |
| Sites | 1 location across United States |
Conditions studied
- Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
- Hematologic Malignancy — all drugs for Hematologic Malignancy →
- Bone Marrow Transplantation — all drugs for Bone Marrow Transplantation →
Sponsor
St. Jude Children's Research Hospital
Who can join
Adults 4 to 21, any sex, with Acute Myeloid Leukemia or Hematologic Malignancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The human microbiome is composed of unique groups of microorganisms occupying distinct habitats distributed throughout the human body. The Human Microbiome Project recently evaluated the bacterial composition of the microbiome in 18 (for women) and 15 (for men) body sites. Much initial attention in the field of microbiome research has focused on the bacterial contribution to a "healthy" microbiome. However, it is clear that other microorganisms, including fungi and viruses, are also distributed throughout the human body and serve as functional components of the microbiome. The populations of microorganisms residing within the oral and nasal cavities make important contributions to human health and disease. These contributions may be especially important in immunosuppressed patients, including those patients receiving myelosuppressive chemotherapy or undergoing hematopoietic stem cell transplantation. In these patients, organisms typically considered as commensals can become pathogenic, either locally or systemically. This observational study is primarily undertaken to evaluate the oral and nasal microbiota and to define the population of fungal organisms residing within the oral and nasal cavities in pediatric oncology patients before and after receiving protocol-directed chemotherapy and associated supportive care.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Much More Than IL-17A: Cytokines of the IL-17 Family Between Microbiota and Cancer.
Brevi A, Cogrossi LL, Grazia G, Masciovecchio D, et al · · 2020 · cited 81× · PMID 33244315 · DOI 10.3389/fimmu.2020.565470 -
Microbial Crosstalk with Therapy: Pharmacomicrobiomics in AML-One Step Closer to Personalized Medicine.
Nowicka A, Tomczak H, Szałek E, Karbownik A, et al · · 2025 · cited 1× · PMID 40722831 · DOI 10.3390/biomedicines13071761
Verify or expand the search:
- PubMed search for NCT02949427
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Myeloid Leukemia
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
- NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
- NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
- NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting
Other St. Jude Children's Research Hospital trials
Trials by the same sponsor.
- NCT07222735 — Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma · Phase 1 · recruiting
- NCT07085338 — A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Pat · Phase 2 · recruiting
- NCT05664113 — Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction i · Phase 1 · recruiting
- NCT06993688 — Revealing Information Genuinely & Honestly Across Time - Communication Preferences Visit · NA · recruiting
- NCT06326463 — CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02949427 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by St. Jude Children's Research Hospital
- Last refreshed: 5 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02949427.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing